Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model

Cellular and molecular characterization of the pirfenidone effects on an hepatocarcinogésis experimental model

Bibliographic Details
Main Authors:	J.A. Silva-Gómez, H.C. Monroy-Ramírez, M. Galicia-Moreno, A. Santos-García, J. Armendáriz-Borunda
Format:	Article
Language:	English
Published:	Elsevier 2020-09-01
Series:	Annals of Hepatology
Online Access:	http://www.sciencedirect.com/science/article/pii/S1665268120301009

Similar Items

Analysis of the molecular interaction of pirfenidone with PPAR-gamma and effects on the beta-catenine pathway in HEPG2 line
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Pirfenidone regulates antioxidant response via NRF2 in an experimental model of hepatocellular carcinoma
by: HC Monroy-Ramírez, et al.
Published: (2022-12-01)

Pirfenidone induces epigenetic changes modulating the activity of the ppargamma-SIRT1-DNMT1 axis in hepatic stellate cells
by: H.C. Monroy-Ramírez, et al.
Published: (2020-09-01)

Pirfenidone slows the development of fibrosis and malignant neoplasms by modulating inflammation in an experimental model of hepatocarcinoma.
by: Scarlet Arceo-Orozco, et al.
Published: (2024-02-01)

Pirfenidone induces translocation of sirt1 to nucleus and deacetylation of histone 3 slows down the development of fibrosis and tumorigenicity in a experimental model of hepatocarcinoma.
by: Hugo C. Monroy-Ramírez, et al.
Published: (2024-02-01)

Prolonged-release pirfenidone prevents myocardial fibrosis in a mouse nonalcoholic steatohepatitis model
by: J. Gutiérrez-Cuevas, et al.
Published: (2020-09-01)

P- 43 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

O-24 PIRFENIDONE PREVENTS NEOPLASTIC LESIONS DEVELOPMENT BY OXIDATIVE, FIBROGENIC, ANTIPROLIFERATIVE AND EPIGENETIC MECHANISMS REGULATION IN A MODEL OF CHEMICAL HEPATOCARCINOGENESIS
by: Hipólito Otoniel Miranda-Roblero, et al.
Published: (2023-03-01)

Pirfenidone Protects from UVB-Induced Photodamage in Hairless Mice
by: Yocasta Martinez-Alvarado, et al.
Published: (2023-03-01)

Hepatocarcinogenesis Prevention by Pirfenidone Is PPARγ Mediated and Involves Modification of Nuclear NF-kB p65/p50 Ratio
by: Jorge Antonio Silva-Gomez, et al.
Published: (2021-10-01)

Prolonged-release pirfenidone decreases hepatic miRNAs expression in a NAFLD/NASH experimental model
by: R. Escutia-Gutiérrez, et al.
Published: (2020-09-01)

Pirfenidone ameliorates MAFLD by improving insulin sensitivity and reducing epididymal fat
by: J. Gutiérrez-Cuevas, et al.
Published: (2022-12-01)

The administration of pirfenidone modifies the expression of JMJD2B in a murine model of NASH
by: JS Rodriguez Sanabria, et al.
Published: (2022-12-01)

Pirfenidone Is an Agonistic Ligand for PPARα and Improves NASH by Activation of SIRT1/LKB1/pAMPK
by: Ana Sandoval‐Rodriguez, et al.
Published: (2020-03-01)

Hepatoprotective effects of N-acetylcysteine prevents hepatocellular carcinoma development induced experimentally.
by: Fernando Caloca-Camarena, et al.
Published: (2024-02-01)

Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH
by: Rebeca Escutia-Gutiérrez, et al.
Published: (2021-06-01)

Roles of Nrf2 in Liver Diseases: Molecular, Pharmacological, and Epigenetic Aspects
by: Marina Galicia-Moreno, et al.
Published: (2020-10-01)

Topical Pirfenidone-Loaded Liposomes Ophthalmic Formulation Reduces Haze Development after Corneal Alkali Burn in Mice
by: Carlos Daniel Diaz-Palomera, et al.
Published: (2022-01-01)

Pirfenidone decreases insulin, glucagon, leptin, plasminogen activator inhibitor 1, preventing nonalcoholic steatohepatitis and myocarditis in an obesity moldel
by: Daniel López-Cifuentes, et al.
Published: (2024-02-01)

Molecular Mechanisms of Obesity-Linked Cardiac Dysfunction: An Up-Date on Current Knowledge
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-03-01)

PPARs as Metabolic Sensors and Therapeutic Targets in Liver Diseases
by: Hugo Christian Monroy-Ramirez, et al.
Published: (2021-08-01)

Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
by: Simón A. Ojeda-Duran, et al.
Published: (2020-05-01)

Editorial: Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies
by: Ana Sandoval-Rodriguez, et al.
Published: (2022-04-01)

Inhibition of Ureteral Stricture by Pirfenidone-Loaded Nanoparticle-Coated Ureteral Stents with Slow-Release Pirfenidone
by: Jiang Z, et al.
Published: (2022-12-01)

Molecular Mechanisms during Hepatitis B Infection and the Effects of the Virus Variability
by: Marina Campos-Valdez, et al.
Published: (2021-06-01)

Perils with Pirfenidone and “the tuberculosis link”
by: Madhav H Hande, et al.
Published: (2019-01-01)

N-acetyl cysteine prevents alterations generated during experimental liver steatosis induced by a chronic consumption of alcohol plus a hypercaloric diet.
by: Marina Galicia-Moreno, et al.
Published: (2024-02-01)

Editorial: Community series - liver fibrosis and MAFLD: from molecular aspects to novel pharmacological strategies, volume II
by: Ana Sandoval-Rodriguez, et al.
Published: (2024-02-01)

The Role of NRF2 in Obesity-Associated Cardiovascular Risk Factors
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2022-01-01)

Pirfenidone and tendon healing: Comment
by: Hinpetch Daungsupawong, et al.
Published: (2024-01-01)

Effect of pirfenidone on tendon healing
by: Yasemin Aydinli, et al.
Published: (2023-01-01)

Biphasic Effect of Pirfenidone on Angiogenesis
by: Donghao Gan, et al.
Published: (2022-01-01)

Oxidative and Fibrinolytic Mechanisms: Two Important Processes to Consider in Platelet Storage
by: Jesus Javier Garcia-Bañuelos, et al.
Published: (2023-03-01)

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases
by: Jorge Gutiérrez-Cuevas, et al.
Published: (2021-10-01)

Efficacy and safety of pirfenidone for idiopathic pulmonary fibrosis
by: Takeda Y, et al.
Published: (2014-03-01)

Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond
by: Alberto Aimo, et al.
Published: (2022-04-01)

Role of pirfenidone in the management of pulmonary fibrosis
by: Meyer KC, et al.
Published: (2017-04-01)

Application of Pirfenidone anti-fibrosis in ophthalmology
by: Xiao Yang, et al.
Published: (2013-08-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Arata Azuma
Published: (2012-04-01)

Pirfenidone treatment of idiopathic pulmonary fibrosis
by: Ye Gan, et al.
Published: (2011-02-01)